Status:
COMPLETED
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arm...
Detailed Description
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Eligibility Criteria
Inclusion
- RRMS patients that are receiving treatment with Avonex 30 µg once weekly
Exclusion
- Primary Progressive or Secondary Progressive MS
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
271 Patients enrolled
Trial Details
Trial ID
NCT00206648
Start Date
March 1 2003
End Date
October 1 2005
Last Update
December 31 2014
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson, Arizona, United States, 85741
2
Berkeley, California, United States, 94705
3
Irvine, California, United States, 92697
4
Loma Linda, California, United States, 92354